The rationale behind starting low is backed by clinical experience: most people tolerate the medication better when introduced gradually rather than at higher doses immediately
Importantly, no serious adverse events were reported in the semaglutide group, and no one had to stop the trial due to side effects
In contrast, the STEP trials evaluating semaglutide at maximum doses showed average weight losses between 15.3% and 17.4% depending on the study population and duration
Finally, we ranked DM2 DMTs based on their Drug Impact Effect Score, identifying those with the highest therapeutic potential for reducing AD comorbidity risk in individuals with DM2 ( see Figure 1c )
New therapies, expanded indications, personalized treatment pathways, and a growing understanding of obesity as a chronic disease are reshaping what effective obesity care looks like